Exanthematous Drug Eruptions
- 28 June 2012
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 366 (26), 2492-2501
- https://doi.org/10.1056/nejmcp1104080
Abstract
Exanthematous (maculopapular) drug eruptions usually begin 4 to 21 days after the responsible drug is started and rapidly evolve into widespread rash. Management includes stopping the drug, prescribing antipruritic therapy, and assessing the patient for severe cutaneous reaction.Keywords
This publication has 46 references indexed in Scilit:
- Epidemiology and risk factors for drug allergyBritish Journal of Clinical Pharmacology, 2011
- HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in EuropeansNew England Journal of Medicine, 2011
- Association of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant useAllergy, 2010
- Role of T cells in nonimmediate allergic drug reactionsCurrent Opinion in Allergy and Clinical Immunology, 2009
- BSACI guidelines for the management of drug allergyClinical and Experimental Allergy, 2009
- Methods for Causality Assessment of Adverse Drug ReactionsDrug Safety, 2008
- Clinical Approach to Cutaneous VasculitisAmerican Journal of Clinical Dermatology, 2008
- Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case–control study (EuroSCAR)British Journal of Dermatology, 2007
- Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical ManagementThe Oncologist, 2007
- Guidelines of care for cutaneous adverse drug reactionsJournal of the American Academy of Dermatology, 1996